Literature DB >> 17563737

Development of T cell-mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of gamma-interferon.

A M T van der Velden1, A M E Claessen, H van Velzen-Blad, D H Biesma, G T Rijkers.   

Abstract

The conditioning regimens for autologous SCT (auto-SCT) lead to impairment of the immune system and concomitant increase in susceptibility to infections. We studied the recovery of cellular immunity by in vitro analysis of T-cell proliferation and cytokine production profiles during the first 15 months after auto-SCT in patients with multiple myeloma and non-Hodgkin's lymphoma. PBMC were collected at 6, 9 and 15 months after transplantation and stimulated with a combination of CD2 and CD28 monoclonal antibodies, with PHA or with tetanus toxoid as recall antigen. A multiplex enzyme linked immunoassay was used to determine levels of Th1 cytokines IL-2, IFN-gamma and tumour-necrosis factor-alpha (TNF-alpha), Th2 cytokines IL-4, IL-5 and IL-13, the regulatory cytokine IL-10 and the proinflammatory cytokines IL-1alpha, IL-1beta, IL-6 and the chemokine IL-8. T-cell proliferation progressively increased from 6 to 15 months after auto-SCT. Overall, cytokine production increased after auto-SCT. Production of Th2 cytokines IL-5 and IL-13 was superior to production of Th1 cytokines IFN-gamma and TNF-alpha. We hypothesize that prolonged impairment of IFN-gamma production might contribute to the relatively high incidence of viral infections after auto-SCT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17563737     DOI: 10.1038/sj.bmt.1705706

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy.

Authors:  Maud Condomines; Jean-Luc Veyrune; Marion Larroque; Philippe Quittet; Pascal Latry; Cécile Lugagne; Catherine Hertogh; Tarik Kanouni; Jean-François Rossi; Bernard Klein
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422

2.  Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.

Authors:  Isabelle Krämer; Melanie Engelhardt; Sabrina Fichtner; Brigitte Neuber; Sergej Medenhoff; Uta Bertsch; Jens Hillengass; Marc-Steffen Raab; Dirk Hose; Anthony D Ho; Hartmut Goldschmidt; Michael Hundemer
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

Review 3.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10

4.  Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells.

Authors:  Fabio Guolo; Paola Minetto; Silvia Pesce; Filippo Ballerini; Marino Clavio; Michele Cea; Michela Frello; Matteo Garibotto; Marco Greppi; Matteo Bozzo; Maurizio Miglino; Monica Passannante; Riccardo Marcolin; Elisabetta Tedone; Nicoletta Colombo; Rosa Mangerini; Alessandra Bo; Maria Rosaria Ruzzenenti; Paolo Carlier; Alberto Serio; Silvia Luchetti; Alida Dominietto; Riccardo Varaldo; Simona Candiani; Vanessa Agostini; Jean Louis Ravetti; Genny Del Zotto; Emanuela Marcenaro; Roberto Massimo Lemoli
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.